SEOUL - Kolon Life Science Inc., which focuses on gene and cell therapies, has unveiled a financing plan to raise production capacity to prepare for the commercialization of Invossa, also known as TissueGene-C, as it aims to file for an approval in South Korea in the first half of this year.
Kolon Ramps Up For Novel Osteoarthritis Cell Therapy
South Korea's Kolon Life Science is gearing up for mass production of Invossa, the world's first cell-mediated gene therapy for osteoarthritis, as it prepares to file for a domestic approval and a US Phase III study. The venture also plans to raise around $114m to hike its biologics production capacity.
More from Focus On Asia
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.